Document text
Principal Investigator: Shioko Kimura
Organization: DIVISION OF BASIC SCIENCES - NCI
Fiscal Year: 2021
Award: $686,816
Funding agency: National Cancer Institute
Previously we found that SCGB3A2 is a lipopolysaccharide (LPS) binding protein, and SCGB3A2-LPS complex binds to a cell surface receptor syndecan-1 (SDC1), and endocytosed cytosolic LPS binds to caspase-11 and activates the non-canonical inflammasome pathway, resulting in pyroptosis. Mouse Lewis lung carcinoma cells had high expression of SDC1 and caspase-11 (CASP11) with strong susceptibility to SCGB3A2-induced growth inhibitory activity while B16F10 melanoma cells had very little expression of SDC1 and CASP11 with no susceptibility to SCGB3A2. These results indicated that the SDC1/CASP11 expression patterns could determine the susceptibility of cancer cells to SCGB3A2-induced anti-tumor activity. Twenty human cancer-derived cell lines (17 lung, 2 colon, and 1 cervix) were examined by in vitro cell culture analysis in the presence of LPS and in vivo xenografts mouse model experiments without additional LPS (endogenous LPS was sufficient), to see if the tumor growth was affected by SCGB3A2. Five out of 11 human non-small cell lung cancer (NSCLC) and two epithelial-derived colon cancer cell lines showed decreased growth by in vitro assays and in mouse xenograft model with administration of SCGB3A2, while no effect was observed in 6 of 6 small cell lung cancer (SCLC) cell lines. All SCGB3A2 sensitive cells expressed SDC1 and caspase-4 (CASP4), a human equivalent to mouse CASP11, a critical component of the non-canonical inflammasome pathway. Lung adenocarcinoma patients with higher SCGB3A2 mRNA levels exhibited better survival by TCGA analysis. Recently, the use of pyroptosis pathway as a cancer treatment has been gaining attention, however, little research has been carried out. SCGB3A2 may serve as a novel therapeutic to treat cancer, perhaps in combination with immuno and/or targeted therapies. Our current research focuses on the use of monophosphoryl lipid A(MPLA), the endotoxin principle of LPS to use instead of LPS in the study of SCGB3A2-LPS anti-cancer activity. LPS is a notorious pro-inflammatory agent, and is a heterogeneous preparation containing large aggregates with various molecular weights, which is not well-suited for studying the nature of SCGB3A2-LPS interaction. In contrast, MPLA is a small molecule, and is safe and widely used as a vaccine adjuvant in humans, suggesting a better alternative to LPS in the study of SCGB3A2-LPS interaction and in vivo studies. SCGB3A2-MPLA interaction is currently being studied using biochemical, biophysical, and cell biological techniques. We also study the effect of SCGB3A2 on COVID-19 infected cells. The plasma level of Interleukin-1beta, a notable cytokine released upon pyroptosis is reported to be elevated in COVID-19 patients, suggesting that pyroptosis is activated in cells infected with SARS-CoV-2. It is known that several of SARS-CoV encoded proteins activate NLRP3, a major player in pyroptosis, while some others are involved in inhibitory reaction of innate immunity. Since SARS-CoV-2 and SARS-CoV share 80% sequence identity, it would be possible that SARS-CoV-2 infection may involve pyroptosis activation, and SCGB3A2 may have the potential to regulate the innate immune response to SARS-CoV-2. Our immediate aim is to determine whether SARS-CoV-2 encoded proteins have any role in canonical and/or non-canonical inflammasome pathways resulting in pyroptosis, and whether SCGB3A2 plays a role in regulating the non-canonical pathway in SARS-CoV-2 infection. We have been preparing adenovirus expressing several SARS-CoV-2 encoded proteins that may be responsible for pyroptotic pathway. The study on the effect of SCGB3A2 on regulating the pyroptotic pathway is ongoing.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><21+ years old><Adenocarcinoma><Adenoviridae><Adenoviruses><Adult><Adult Human><Affect><Anti-Inflammatories><Anti-Inflammatory Agents><Anti-inflammatory><Antiinflammatories><Antiinflammatory Agents><Asthma><Attention><Beta Proprotein Interleukin 1><Binding><Biochemical><Biological><Biological Function><Biological Process><Biophysics><Blood Plasma><Bronchial Asthma><CASP11><CASP4><CASP4 gene><COPD><COVID infected patient><COVID patient><COVID positive patient><COVID-19><COVID-19 infected patient><COVID-19 infection><COVID-19 patient><COVID-19 positive patient><COVID-19 virus><COVID19><COVID19 infection><COVID19 patient><COVID19 positive patient><COVID19 virus><CV-19><CV19><Cancer Treatment><Cancer cell line><Cancers><Caspase><Caspase Gene><Cell Body><Cell Culture Techniques><Cell Death><Cell Line><Cell Surface Receptors><Cell-Death Protease><CellLine><Cells><Cervix><Cervix Uteri><Characteristics><Chronic Obstruction Pulmonary Disease><Chronic Obstructive Airway Disease><Chronic Obstructive Lung Disease><Chronic Obstructive Pulmonary Disease><CoV-2><CoV2><Colon><Complex><Cysteine Endopeptidases><Cysteine Protease><Cysteine Proteinases><Disease><Disorder><Drugs><Endotoxins><Epithelial><Exhibits><Family member><Generalized Growth><Genes><Goals><Growth><Growth Agents><Growth Factor><Growth Substances><Heterograft><Heterologous Transplantation><Homo><Human><ICE and CED3 Homolog 2><ICE-like protease><ICH-2><IL-1 beta><IL-1 β><IL-1-b><IL-1β><IL1-Beta><IL1-β><IL1B Protein><IL1F2><IL1β><Immune mediated therapy><Immunologically Directed Therapy><Immunomodulation><Immunotherapy><In Vitro><Inflammasome><Inflammatory><Innate Immune Response><Innate Immunity><Interleukin 1beta><Interleukin-1 beta><Interleukin-1β><LLC1><LPS-binding protein><Lacrimal Glands><Lacrimal gland structure><Lewis lung carcinoma cell><Lipid A><Lipopolysaccharides><Lung><Lung Adenocarcinoma><Lung Respiratory System><Lung diseases><Malignant Adenoma><Malignant Cell><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Malignant Tumor of the Lung><Malignant neoplasm of lung><Medication><Melanoma Cell><Messenger RNA><Mice><Mice Mammals><Modern Man><Molecular Interaction><Molecular Weight><Mouse Homolog of Caspase 11><Murine><Mus><NSCLC><NSCLC - Non-Small Cell Lung Cancer><Native Immunity><Natural Immunity><Nature><Non-Small Cell Lung Cancer><Non-Small-Cell Lung Carcinoma><Non-Specific Immunity><Nonsmall Cell Lung Carcinoma><Nonspecific Immunity><Oat cell carcinoma><Organ Culture><Organ Culture Techniques><Pathway interactions><Patients><Pattern><Pharmaceutic Preparations><Pharmaceutical Preparations><Physiology><Plasma><Plasma Serum><Play><Predisposition><Preinterleukin 1 Beta><Premature Infant><Preparation><Prostate><Prostate Gland><Prostatic Gland><Protein Family><Proteins><Proteins Growth Factors><Pulmonary Cancer><Pulmonary Diseases><Pulmonary Disorder><Pulmonary Fibrosis><Pulmonary malignant Neoplasm><Reaction><Receptor Protein><Recombinants><Reporting><Research><Respiratory Disease><Respiratory System Disease><Respiratory System Disorder><Reticuloendothelial System, Serum, Plasma><Role><SARS Virus><SARS corona virus><SARS corona virus 2><SARS coronavirus><SARS-Associated Coronavirus><SARS-CoV><SARS-CoV-2><SARS-CoV-2 infected patient><SARS-CoV-2 infection><SARS-CoV-2 patient><SARS-CoV-2 positive patient><SARS-CoV2><SARS-CoV2 infection><SARS-Related Coronavirus><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Salivary Glands><Salivary Glands Head and Neck><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome related corona virus 2><Site><Small Cell Lung Cancer><Strains Cell Lines><Surface><Susceptibility><TCGA><Techniques><The Cancer Genome Atlas><Tissue Growth><Uterine Cervix><Uterus><Vaccine Adjuvant><Wuhan coronavirus><Xenograft><Xenograft Model><Xenograft procedure><Xenotransplantation><adulthood><airway epithelium><anti-cancer activity><anti-cancer therapy><anticancer activity><anticancer therapy><antiinflammatory><biophysical foundation><biophysical principles><biophysical sciences><cancer cell><cancer therapy><cancer-directed therapy><cell culture><colo-rectal cancer cell line><colon cancer cell line><colorectal cancer cell line><corona virus disease 2019><coronavirus disease 2019><coronavirus disease 2019 infected patient><coronavirus disease 2019 infection><coronavirus disease 2019 patient><coronavirus disease 2019 positive patient><coronavirus disease 2019 virus><coronavirus disease infected patient><coronavirus disease patient><coronavirus disease positive patient><coronavirus patient><cultured cell line><cystein protease><cystein proteinase><cysteine endopeptidase><cytokine><diagnostic biomarker><diagnostic marker><disease of the lung><disorder of the lung><drug/agent><experiment><experimental research><experimental study><hCoV19><immune modulation><immune regulation><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><immunologic reactivity control><immunomodulatory><immunoregulation><immunoregulatory><in vitro Assay><in vitro Organ Culturing><in vitro vertebrate organ culturing><in vivo><infants born premature><infants born prematurely><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><lipopolysaccharide-binding protein><lung cancer><lung disorder><lung fibrosis><lung oat cell carcinoma><lung small cell carcinoma><lung small cell neuroendocrine carcinoma><mRNA><malignancy><member><mouse model><murine model><nCoV2><necrocytosis><neoplasm/cancer><new drug treatments><new drugs><new therapeutics><new therapy><next generation therapeutics><nonsmall cell lung cancer><novel><novel drug treatments><novel drugs><novel therapeutics><novel therapy><oat cell cancer><ontogeny><pathway><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><premature baby><premature infant human><preterm baby><preterm infant><preterm infant human><pulmonary><receptor><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 positive patient><severe acute respiratory syndrome-CoV><small cell undifferentiated carcinoma><small molecule><social role><syndecan><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><tumor><tumor growth><womb><xeno-transplant><xeno-transplantation><xenograft transplant model><xenotransplant model>